GLFD Guilford Pharmaceuticals (MM)

Guilford Pharmaceuticals to Host Webcast Outlining New Corporate Strategy BALTIMORE, April 5 /PRNewswire-FirstCall/ -- Guilford Pharmaceuticals Inc. (NASDAQ:GLFD) will host a webcast on April 6, 2005, beginning at approximately 12:15 p.m. Eastern Daylight Time, to outline the Company's new corporate strategy and review results from a Phase III clinical trial of AQUAVAN(R) Injection, a novel sedative/hypnotic in development for use in procedural sedation. Dean Mitchell, President and Chief Executive Officer, and William Spengler, Executive Vice President and Chief Financial Officer will outline the Company's new corporate strategy, financial goals and upcoming milestones. Following their remarks, Dr. Lawrence Cohen, Associate Clinical Professor, Division of Gastroenterology, Mount Sinai Hospital, New York, will review the results of the Phase III AQUAVAN(R) colonoscopy trial. To access the webcast, visit Guilford's website at http://www.guilfordpharm.com/. The link for the webcast is available under the 'Investor' section under 'Conferences.' The webcast is scheduled to begin at approximately 12:15 p.m. EDT. An archived version of the webcast will be available until April 20, 2005. To listen to live audio from the webcast, dial 800-901-5241, international callers may dial 617-786-2963. The participant passcode is 17581864. An audio replay will be available beginning at approximately 2:00 p.m. April 6, 2005 until April 20, 2005. The dial-in number for the audio replay is 888-286-8010, international callers may dial 617-801-6888. The passcode for the audio replay is 84190925. About Guilford Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary pharmaceutical products that target the hospital and neurology market. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer (polifeprosan 20 with carmustine implant), for the treatment of brain cancer, and AGGRASTAT(R) Injection (tirofiban hydrochloride), a glycoprotein GP IIb/IIIa receptor antagonist used for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel sedative, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and post-prostatectomy erectile dysfunction. For additional information about GLIADEL(R) and AGGRASTAT(R), please see http://www.guilfordpharm.com/ under Products / Marketed Products. This press release contains forward-looking statements that involve risks and uncertainties, including those described in the section entitled "Risk Factors" contained in the Company's Annual Report on Form 10-K filed with the SEC on March 7, 2005, that could cause the Company's actual results and experience to differ materially from anticipated results and expectations expressed in these forward-looking statements. Contact: Guilford Pharmaceuticals Inc. Stacey Jurchison 410.631.5022 DATASOURCE: Guilford Pharmaceuticals Inc. CONTACT: Stacey Jurchison, Guilford Pharmaceuticals Inc., +1-410-631-5022, Web site: http://www.guilfordpharm.com/ Company News On-Call: http://www.prnewswire.com/comp/112882.html

Copyright